Primary treatment of Crohn's disease: Combined antibiotics taking center stage

Expert Review of Clinical Immunology

Volumn 7, Issue 6, 2011, Pages 751-760

  Chamberlin, William ^a   Borody, Thomas J ^b   Campbell, Jordana ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Centre for Digestive Diseases   (Australia)

Author keywords

anti MAP therapy; Crohn's disease; Mycobacterium avium paratuberculosis

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BUDESONIDE; CIPROFLOXACIN; CLOFAZIMINE; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; PLACEBO; PREDNISONE; RIFABUTIN;

ANTIBIOTIC THERAPY; CLINICAL TRIAL (TOPIC); COLONOSCOPY; COMBINATION CHEMOTHERAPY; CROHN DISEASE; ENTEROBACTERIACEAE; HUMAN; META ANALYSIS (TOPIC); MUCOSAL IMMUNITY; REVIEW; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIA; CROHN DISEASE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNITY, MUCOSAL; INTESTINES; MEDLINE;

EID: 80054905973     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.43     Document Type: Review

References (69)

1. Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm. Bowel Dis. 12(7), 651-664 (2006)
2. Podolsky DK. Inflammatory bowel disease. N. Engl. J. Med. 347, 417-429 (2002)
3. Akbulut S, Yavuz B, Koseoglu T, et al. Crohn's disease with isolated esophagus and gastric involvement. Turk. J. Gastroenterol. 15(3), 196-200 (2004)
4. Malleson P. Isolated gastroduodenal Crohn's disease in a ten-year-old girl. Postgrad. Med. J. 56, 294-296 (1980)
5. Kotanagi H, Sone S, Fukuoka T, et al. Liver abscess as the initial manifestation of colonic Crohn's disease: report of a case. Surgery Today 21(3), 348-351 (2007)
6. Ulnick KM, Perkins J. Extraintestinal Crohn's disease: case report and review of the literature. Ear Nose Throat J. 80(2), 97-100 (2001)
7. Sartor BR. Pathogenesis of Crohn's disease and ulcerative colitis: specific theories. Nat. Clin. Prac. Gastroenterol. Hepatol. 3(7), 390-407 (2006)
8. Blichfeldt P, Blonhoff JP, Myhre E, et al. Metronidazole in Crohn's disease. A double-blind cross-over clinical trial. Scand. J. Gastroenterol. 13, 123-127 (1978)
9. Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II Result. Gastroenterology 83, 550-562 (1982)
10. Ambrose NS, Allan RN, Keighley MR, et al. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. Dis. Colon Rectum 28, 81-85 (1985)
11. Sutherland L, Singleton J, Sessions J, et al. Double-blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 32, 1071-1075 (1991)
12. De'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 135(4), 1123-1129 (2008)
13. Feller M, Huwiler K, Schoepfer A, et al. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin. Infect Dis. 50(4), 473-480 (2010)
14. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's disease? J. Clin. Gatroenterol. 17, 235-237 (1993)
15. Arnold GL, Beaves MR, Pyrjdun VO, et al. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm. Bowel Dis. 8, 10-15 (2002)
16. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic treatment regimen for the treatment of active Crohn's disease. A randomized controlled clinical trial of metronidazole plus ciprofloxacin. Am. J. Gastroenterol. 91, 328-332 (1996)
17. Colombel JF, Lehman M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETARD). Am. J. Gastroenterol. 94, 674-678 (1999)
18. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease. A randomized controlled trial. Gastroenterology 123, 33-40 (2002)
19. Prantera C, Berto E, Scribano ML, et al. Use of antibiotics in the treatment of active Crohn's disease. Experience with metronidazole and ciprofloxacin. Ital. J. Gastroenterol. Hepatol. 30, 602-606 (1998)
20. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can. J. Gastroenterol. 12, 53-56 (1998)
21. Khan K, Ullman T, Ford A, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 106(4), 661-673 (2011)
22. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's Disease: current management. J. Crohn's Colitis 4, 28-62 (2010)
23. Shafran I. Burgeunder P. Rifaximin for the treatment of newly diagnosed Crohn's disease: a case series. Am. J. Gasteroenterol. 103, 2158-2160 (2008)
24. Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr. Med. Res. Opin. 21, 1165-1169 (2005)
25. Shafran I, Burgunder P. Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity. Dig. Dis. Sci. 55, 1079-1084 (2010)
26. Warren J, Rees H, Cox T. Remission of Crohn's disease with tuberculosis chemotherapy. N. Engl. J. Med. 314, 182 (1986)
27. Schultz M, Rieder H, Hersh T, et al. Remission of Crohn's disease with antibacterial chemotherapy. Lancet 330, 1391-1392 (1987)
28. Ward M, McManus JP. Dapsone in Crohn's disease. Lancet 1, 1236-1237 (1975)
29. Prantera C, Argentieri R, Mangiarotti R, et al. Dapsone and remission of Crohn's disease. Lancet 1(8584), 536 (1988)
30. Prantera C, Bothamley G, Levenstein S, et al. Crohn's disease and mycobacteria: two cases of Crohn's disease with high anti-mycobacterial antibody levels cured by dapsone therapy. Biomed. Pharmacother. 43(4), 295-299 (1989)
31. Shaffer JL, Hughes S, Linaker BD, et al. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut 25, 203-205 (1984)
32. Jarnerot G, Rolny P, Wickbom G, et al. Antimycobacterial therapy ineffective in Crohn's disease after a year. Lancet 1, 164-165 (1989)
33. Swift GL, Srivastava ED, Stone R, et al. Controlled trial of anti-tuberculosis chemotherapy for two years in Crohn's disease. Gut. 35, 363-368 (1994)
34. Rutgeerts P, Geboes K, Vantrappen G, et al. Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum. J. Clin. Gastroenterol. 15, 24-28 (1992)
35. Hampson S, Parker M, Saverymutter S, et al. Quadruple antimycobacterial chemotherapy in Crohn's disease: results at 9 months of a pilot study in 20 patients. Aliment. Pharmacol. Ther. 3(4), 343-352 (1989)
36. Prantera C, Kohn A, Mangiarotti R, et al. Antimycobacterial therapy in Crohn's disease: results of a controlled double-blind trial with a multiple antibiotic regimen. Am. J. Gastroenterol. 89(4), 513-518 (1994)
37. Afdhal NH, Long A, Lennon J, et al. Controlled trial of antimycobacterial therapy in Crohn's disease: clofazimine versus placebo. Dig. Dis. Sci. 36, 449-453 (1991)
38. Graham DY, Al-Assi MT, Robinson M. Prolonged remission in Crohn's disease following therapy for Mycobacterium paratuberculosis infection. Gastroenterology 108, A826 (1995)
39. Leiper M. Open label trial of oral clarithromycin in active Crohn's disease. Aliment. Pharmacol. Ther. 14(6), 801-806 (2000)
40. Inoue S, Nakase H, Matsuura M, et al. Open label trial of clarithromycin therapy in Japanese patients with Crohn's disease. J. Gastro. Hepatol. 22, 984-988 (2007)
41. Mitchell JD, Bishop A, Cafaro A, et al. Anatomic lung resection for nontuberculous mycobacterial disease. Ann. Thorac. Surg. 85, 1887-1893 (2008)
42. Gangadharam, PR, Perumal, VK, Jairam, BT, et al. Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. Am. Rev. Respir. Dis. 136, 329-333 (1987)
43. Hornick DB, Dayton CS, Bedell GN, et al. Nontuberculous mycobacterial lung disease. Substantiation of a less aggressive approach. Chest 93(3), 550-555 (1988)
44. Chiodini RJ. Antimicrobial activity of rifabutin in combination with two and three other antimicrobial agents against strains Mycobacterium avium paratuberculosis. J. Antimicrob. Chemother. 27, 171-176 (1991)
45. Blasquez J, Oliver A, Gomez-Gomez JM. Mutation and evolution of antibiotic resistance: antibiotics as promoters of antibiotic resistance? Curr. Drug Targets 3(4), 345-349 (2002)
46. Ghebremichael S, Svenson SB, Kallenius G, et al. Antimycobacterial synergism of clarithromycin and rifabutin. Scan. J. Infect. Dis. 28, 387-390 (1996)
47. Rastogi N, Goh KS, Labrousse V. Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement its extracellular and intracellular activities by ethambutol. Antimicrob. Agents Chemother. 36, 2843-2846 (1992)
48. Gui GPH, Thomas PRS, Tizard MLV, et al. Two-year outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J. Antimicrob. Chemother. 39(3), 393-400 (1997)
49. Douglas A, Bramble MG, Silcock JC. Antimycobacterial treatment for Crohn's disease: does it prevent surgery and how fast does it act? Gut 48, A89 (2000)
50. Borody TJ, Leis S, Warren EF, et al. Treatment of severe Crohn's disease using antimycobacterial triple therapy - approaching a cure? Dig. Liver Dis. 34(1), 29-38 (2002)
51. Shafran I, Kugler L, El-Zaatari FA, et al. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig. Liver Dis. 34(1), 22-28 (2002)
52. Borody TJ, Bilkey S, Wettstein AR, et al. Australian Gastroenterology Week Meeting. Brisbane, Queensland, Australia, 19-22 October 2005
53. Borody TJ, Bilkey S, Wettstein AR, et al. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. Dig. Liver Dis. 39(5), 438-444 (2007)
54. Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin and clofazimine for Crohn's disease. Gastroenterology 132(7), 2313-2319 (2007)
55. Behr M, Kapur V. The evidence for Mycobacterium paratuberculosis in Crohn's disease. Curr. Opin. Gastroenterol. 24(1), 17-21 (2008)
56. Biroulet LP, Neut C, Colombel JF. Antimycobacterial therapy in Crohn's disease: the end of a long controversy? Prac. Gastro. 1, 11-17 (2008)
57. Yunzhao RR, Pan F, Parvez S, et al. Clofazamine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One 3(12), e4009 (2008)
58. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 359, 1541-1549 (2002)
59. Keunstner J. Australian Crohn's Antibiotic Study opens new horizons. Gastroenterology 133(5), 1743-1744 (2007)
60. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132(1), 52-65 (2007)
61. Moore TJ, Cohen MR, Furberg CD, et al. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch. Intern. Med. 167(16), 1752-1759 (2007)
62. Lees C, Ali A, Thompson AI, Ho GT, et al. The safety profile of anti-TNF therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment. Pharmacol. Ther. 29(3), 286-297 (2009)
63. Chamberlin W, Ghobrial G, Chehtane M, et al. Successful treatment of a Crohn's disease patient infected with bacteremic Mycobacterium paratuberculosis. Am. J. Gastroenterol. 102, 689-691 (2007)
64. Rahimi R, Shekoufeh N, Rezaie A, et al. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease. Clin. Ther. 28(12), 1983-1988 (2006)
65. Netea MG, Joosten LA. A NOD for autophagy. Nature Med. 16, 28-30 (2010)
66. Hayee B, Rahman F, Sewell G, et al. Crohn's disease as an immunodeficiency. Expert Rev. Clin. Immunol. 6(4), 585-596 (2010)
67. Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N. Engl. J. Med. 352, 2193-2201 (2005)
68. Nicoletti F, Conrad D, Wang A, et al. 16a-bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs. Clin. Exp. Immunol. 158(3), 308-316 (2009)
69. Levin BR, Bull JJ. Population and evolutionary dynamics of phage therapy. Nat. Rev. Micro. 2, 166-173 (2004)